NYSE:ENFN

Enfusion (ENFN) Stock Forecast, Price & News

$7.88

+0.08 (+1.03%)

(As of 05/26/2023 ET)

Compare

Today's Range: $7.79
▼
$8.03
50-Day Range: $7.54
▼
$10.50
52-Week Range: $7.37
▼
$16.76

Volume: 571,676 shs
Average Volume: 404,192 shs
Market Capitalization: $916.37 million

P/E Ratio: 197.05
Dividend Yield: N/A
Price Target: $11.08

Enfusion MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 40.7% Upside
$11.08 Price Target
Short Interest: Healthy
4.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.14
Based on 6 Articles This Week
Insider Trading: Selling Shares
$11.56 M Sold Last Quarter
Proj. Earnings Growth: 66.67%
From $0.12 to $0.20 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Computer And Technology Sector

108th out of 623 stocks

Prepackaged Software Industry

28th out of 217 stocks

3.0

Analyst's Opinion

Consensus Rating
Enfusion has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $11.08, Enfusion has a forecasted upside of 40.7% from its current price of $7.88.
Amount of Analyst Coverage
Enfusion has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.47% of the float of Enfusion has been sold short.
Short Interest Ratio / Days to Cover
Enfusion has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Enfusion has recently decreased by 0.75%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Enfusion does not currently pay a dividend.
Dividend Growth
Enfusion does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENFN.

1.7

News and Social Media Coverage

News Sentiment
Enfusion has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Computer and Technology companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Enfusion this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for ENFN on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Enfusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,555,367.00 in company stock.
Percentage Held by Insiders
40.10% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
49.38% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Enfusion are expected to grow by 66.67% in the coming year, from $0.12 to $0.20 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Enfusion is 197.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 132.69.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enfusion is 197.05, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 339.95.
Price to Earnings Growth Ratio
Enfusion has a PEG Ratio of 1.32. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Enfusion has a P/B Ratio of 9.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Enfusion (NYSE:ENFN) Stock

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.

Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

ENFN Stock News Headlines

May 26, 2023 | americanbankingnews.com

Enfusion (NYSE:ENFN) Stock Price Up 2.7%

May 25, 2023 | businesswire.com

Enfusion To Present at the 43 rd Annual William Blair Growth Stock Conference

May 28, 2023 | Behind the Markets (Ad)

NOTICE: Your retirement is in immediate danger

Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>

May 25, 2023 | finance.yahoo.com

Enfusion To Present at the 43rd Annual William Blair Growth Stock Conference

May 22, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Hold Rating on Enfusion (ENFN)

May 22, 2023 | americanbankingnews.com

Enfusion (NYSE:ENFN) Price Target Lowered to $9.00 at Piper Sandler

May 11, 2023 | seekingalpha.com

Enfusion, Inc. 2023 Q1 - Results - Earnings Call Presentation

May 9, 2023 | finance.yahoo.com

Bull Of The Day: Enfusion (ENFN)

May 28, 2023 | Behind the Markets (Ad)

NOTICE: Your retirement is in immediate danger

May 9, 2023 | finance.yahoo.com

Enfusion, Inc. (ENFN) Q1 Earnings Meet Estimates

May 8, 2023 | americanbankingnews.com

Enfusion (ENFN) to Release Quarterly Earnings on Tuesday

May 5, 2023 | finance.yahoo.com

Enfusion (ENFN) to Report Q1 Earnings: What's in the Offing?

May 5, 2023 | finance.yahoo.com

Fewer Investors Than Expected Jumping On Enfusion, Inc. (NYSE:ENFN)

May 2, 2023 | msn.com

Enfusion, Inc. (ENFN) Flat As Market Sinks: What You Should Know

May 2, 2023 | finance.yahoo.com

Enfusion, Inc. (ENFN) Q1 Earnings Preview: What's in the Cards?

May 2, 2023 | finance.yahoo.com

Global SaaS Leader Zone & Co Appoints Seasoned FinTech Exec Thomas Kim as New CEO

April 26, 2023 | finanznachrichten.de

Enfusion, Inc.: Enfusion Announces Date of First Quarter 2023 Results

April 25, 2023 | finance.yahoo.com

Bears are Losing Control Over Enfusion, Inc. (ENFN), Here's Why It's a 'Buy' Now

April 24, 2023 | finance.yahoo.com

Enfusion, Inc. (ENFN) Outpaces Stock Market Gains: What You Should Know

April 21, 2023 | finance.yahoo.com

After Plunging -14.72% in 4 Weeks, Here's Why the Trend Might Reverse for Enfusion, Inc. (ENFN)

April 20, 2023 | finance.yahoo.com

Enfusion Announces Date of First Quarter 2023 Results

April 20, 2023 | americanbankingnews.com

Enfusion, Inc. (NYSE:ENFN) CTO Dan Groman Sells 3,877 Shares of Stock

April 15, 2023 | americanbankingnews.com

Enfusion (NYSE:ENFN) Sees Strong Trading Volume

April 9, 2023 | seekingalpha.com

Enfusion: Still Very Attractive

April 7, 2023 | finance.yahoo.com

Enfusion, Inc. (ENFN) Interactive Stock Chart - Yahoo Finance

April 6, 2023 | finance.yahoo.com

Enfusion Announces Partnership With Leading Risk Management Provider Qontigo

April 3, 2023 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Enfusion

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

ENFN Company Calendar

Last Earnings: 3/07/2023
Today: 5/27/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Prepackaged software
Sub-Industry: N/A
Sector: Computer and Technology
Current Symbol: NYSE:ENFN
CUSIP: N/A
CIK: 1868912
Web: www.enfusion.com
Phone: 312-253-9800
Fax: N/A
Employees: 1,006
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.08
High Stock Price Forecast: $14.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +40.7%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.04
Trailing P/E Ratio: 197.05
Forward P/E Ratio: 65.67
P/E Growth: 1.32
Net Income: $-7,650,000.00
Net Margins: 1.81%
Pretax Margin: 3.36%
Return on Equity: 2.81%
Return on Assets: 2.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.32
Quick Ratio: 6.32

Sales & Book Value

Annual Sales: $150.35 million
Price / Sales: 6.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.85 per share
Price / Book: 9.27

Miscellaneous

Outstanding Shares: 116,290,000
Free Float: 69,655,000
Market Cap: $916.37 million
Optionable: Not Optionable
Beta: 0.43

Key Executives

Mr. Oleg Movchan (Age 49)
CEO & Director

Mr. Stephen Malherbe
Managing Partner

Mr. Bradley Herring (Age 52)
Chief Financial Officer

Mr. Michael Berry
Chief Operating Officer

Mr. Daniel Groman (Age 34)
Chief Technology Officer

Mr. Brian Murphy
Investor

Ms. Lorelei M. Skillman (Age 53)
Chief Marketing & Communications Officer

Ms. Bronwen Bastone (Age 50)
Chief People Officer

Mr. Kabir Kohli
MD of Managed Services Solutioning & Global Head of Client Services

Mr. Joseph Defeo
Global Head of Managed Services Production

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ENFN Stock - Frequently Asked Questions

Should I buy or sell Enfusion stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ENFN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENFN, but not buy additional shares or sell existing shares.
View ENFN analyst ratings or view top-rated stocks.
What is Enfusion's stock price forecast for 2023?: 5 brokers have issued 1 year target prices for Enfusion's stock. Their ENFN share price forecasts range from $9.00 to $14.00. On average, they anticipate the company's share price to reach $11.08 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price.
View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts.
How have ENFN shares performed in 2023?: Enfusion's stock was trading at $9.67 on January 1st, 2023. Since then, ENFN shares have decreased by 18.5% and is now trading at $7.88.
View the best growth stocks for 2023 here.
When is Enfusion's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ENFN earnings forecast.
How were Enfusion's earnings last quarter?: Enfusion, Inc. (NYSE:ENFN) posted its quarterly earnings results on Tuesday, March, 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $40.52 million for the quarter, compared to analysts' expectations of $39.88 million. Enfusion had a net margin of 1.81% and a trailing twelve-month return on equity of 2.81%.
What ETF holds Enfusion's stock ?: Direxion Daily Cloud Computing Bull 2x holds 378 shares of ENFN stock, representing 0.05% of its portfolio.
What guidance has Enfusion issued on next quarter's earnings?: Enfusion issued an update on its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $185.00 million-$190.00 million, compared to the consensus revenue estimate of $188.13 million.

When did Enfusion IPO?: (ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share.
What is Enfusion's stock symbol?: Enfusion trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENFN."
Who are Enfusion's major shareholders?: Enfusion's stock is owned by a number of institutional and retail investors. Top institutional investors include Brown Capital Management LLC (7.26%), BlackRock Inc. (1.35%), New York State Common Retirement Fund (1.05%), New York State Common Retirement Fund (1.05%), Wasatch Advisors LP (0.48%) and State Street Corp (0.45%). Insiders that own company stock include Dan Groman, Hillhouse Investment Managemen, Roy Luo, Stephen Malherbe and Tarek Hammoud.
View institutional ownership trends.
How do I buy shares of Enfusion?: Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Enfusion's stock price today?: One share of ENFN stock can currently be purchased for approximately $7.88.
How much money does Enfusion make?: Enfusion (NYSE:ENFN) has a market capitalization of $916.37 million and generates $150.35 million in revenue each year. The company earns $-7,650,000.00 in net income (profit) each year or $0.04 on an earnings per share basis.
How many employees does Enfusion have?: The company employs 1,006 workers across the globe.
How can I contact Enfusion?: The official website for the company is www.enfusion.com. The company can be reached via phone at 312-253-9800 or via email at brian.murphy@icrinc.com.

This page (NYSE:ENFN) was last updated on 5/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial